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Radiotherapy is employed in the treatment of over 50% of cancer patients. However, this 
therapy approach is limited to mainly treating localized disease. In 1953, Mole described 
the remarkable abscopal effect, whereby, localized radiotherapy of a patient’s primary 
tumor might engender regression of cancer at distant sites, which were not irradiated. 
Current consensus is that if the abscopal effect can be efficaciously leveraged, it would 
transform the field of radiation oncology, extending the use of radiotherapy to treatment 
of both localized and metastatic disease. A close examination of the literature on the 
abscopal effect proffers a disruptive new hypothesis for consideration in future clinical 
trials. This hypothesis is that generating a subcutaneous human tumor autograft as 
the primary tumor may be a more efficacious approach to prime the abscopal effect. 
Following the preclinical data, the merits and demerits of such an approach are exam-
ined in this article.
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introdUCtion
Radiotherapy is a crucial component of cancer care used in the treatment of over 50% of cancer 
patients either alone or in combination with other treatments. However, this therapy approach is 
generally prescribed for treatment of localized disease. In 1953, Mole described the abscopal effect 
(1) whereby localized radiotherapy at one site might engender tumor regression at distant untreated 
sites. Unfortunately, the abscopal responses to radiotherapy alone are rare (2). In fact, since Mole’s 
report, only a limited number of cases on the abscopal effect have been reported when using radio-
therapy alone. However, it soon became apparent that if this potent effect was efficaciously leveraged, 
it could transform radiotherapy practice. It would significantly extend the use of radiotherapy to 
treating both localized and metastatic disease. The impact would be major since cancer metastasis 
accounts for over 90% of all cancer-associated suffering and death.
A more modern understanding of the abscopal effect is that it is an immune modulation effect 
of radiotherapy. In a landmark study in 2004, the abscopal effect was first connected to mechanisms 
involving the immune system (3). The study showed that the effect could not occur in T  cell-
deficient mice. Subsequent studies have corroborated this, and it has become apparent that, in some 
cases, radiotherapy may successfully immunize a patient against cancer, converting the irradiated 
tumor into an in situ vaccine (4). In other words, the patient’s immune system may be triggered 
for a systemic rejection of cancer by treating a tumor lesion locally. The modus operandi for such 
in situ vaccination is that the radiotherapy beam first inflicts damage on the cancer cells, eliciting 
taBLe 1 | preclinical studies demonstrating the abscopal effect when 
using radiotherapy in conjunction with immunoadjuvants.
tumor type irradiated site; dose immunoadjuvant; 
dose
reference
Lewis lung 
carcinoma
Subcutaneous flank; 
6 Gy
Anti-CD40; 20 µg Ngwa et al. (11)
67NR 
mammary 
carcinoma
Subcutaneous; 
3 Gy × 8 Gy
Fms-like tyrosine 
kinase receptor 
3 ligand (Flt3-L); 
10 µg × 10
Habets et al. (12)
TUBO 
mammary/
MCA38 colon
Subcutaneous flank; 
12 Gy
Anti-PD-L1; 
200 µg × 4
Deng et al. (13)
FM3A 
mammary
Subcutaneous flank; 
6 Gy
ECI301; 600 ng Kanegasaki  
et al. (14)
Colon26 Subcutaneous flank; 
20 Gy
IL-2; 20,000 U in 
0.1 mL of PBS
Yasuda et al. (15)
TSA 
mammary/
MCA38 colon
Subcutaneous flank; 
20, 24, and 30 Gy
9H10; 200 µg × 3 Dewan et al. (16)
Colon26/
MethA 
sarcoma/LLC
Subcutaneous flank; 
6 Gy
ECI301, 2 µg × 3 Shiraishi et al. (17)
SCC VII Subcutaneous femur; 
4–10 Gy
DC Akutsu et al. (18)
4T1 mammary Subcutaneous flank; 
12–24 Gy
9H10 Demaria et al. (19)
67NR 
mammary
Subcutaneous flank, 
flank; 2–6 Gy
Flt3-L Demaria et al. (3)
D5 melanoma/
MCA 205 
sarcoma 
MethA
Subcutaneous flank; 
42.5 Gy
DC Teitz-Tennenbaum 
et al. (20)
C3 cervical/
sarcoma
Subcutaneous hind 
leg; 30–50 Gy
DC Nikitina and 
Gabrilovich (21)
LCC Subcutaneous foot; 
60 Gy
Flt3-L Chakravarty  
et al. (22)
LCC, Lewis lung carcinoma; DCs, dendritic cells; SCC, squamous cell carcinoma.
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phenotypic changes, and the release of neoantigens (5, 6). The 
neoantigens can be taken up by antigen-presenting cells (APCs) 
with the unique ability to process antigenic proteins into suit-
able peptide fragments, to incorporate them into MHC class 
I and II molecules, and to present them to T  cells. It has also 
been shown that cancer cell surface expression of MHC class I 
molecules increases after radiotherapy and in a dose-dependent 
manner, leading to the recognition of irradiated cells by cytotoxic 
T  lymphocytes (7). Altogether, these and other studies support 
the fact that the abscopal effect is immune-mediated with direct 
involvement of T cells.
Given the ability of radiotherapy to convert tumors into an 
in situ vaccine, it follows that the addition of appropriate immu-
noadjuvants could enhance or prime the immune-mediated 
abscopal effect and increase response rates. The abscopal effect 
should really be considered as a product of the multimodal cancer 
treatment. In fact, many preclinical studies that have demon-
strated effective abscopal responses employ immunoadjuvants 
(Table  1). These preclinical studies have provided justification 
for clinical trials (8, 9), where abscopal responses are detected 
in patients treated with radiation therapy and immunoadjuvants, 
for different indications. In this approach, illustrated in Figure 1, 
the immunoadjuvants can be employed to target and enhance 
different aspects of the abscopal effect process. For example, anti-
CD40 can be employed to enhance activation of APCs (9), granu-
locyte macrophage colony-stimulating factor (GM-CSF) can be 
used to increase the percentage of APCs, while anti-CTLA4 or 
PD-1 can act as immune checkpoint inhibitors, enhancing T cell 
action on the tumor cells (9, 10).
In a recent prospective clinical trial, using GM-CSF, absco-
pal responses occurred in 11 of 41 accrued patients (8). In 
another study, Grimaldi et al. reported a 52% abscopal response 
rate among 21 patients with melanoma who progressed after 
receiving the immunoadjuvant ipilimumab (anti-CTLA4) 
during palliative radiotherapy (23). Noteworthy, in this report, 
was an indication that a local response was a prerequisite for 
priming an abscopal effect. Furthermore, a 2015 review article 
by Reynders et al. (24) described 23 case reports and 13 pre-
clinical studies on the abscopal effect. They observed that 11 of 
the 13 preclinical studies used immunoadjuvants to achieve an 
abscopal response. Altogether, these findings strongly suggest 
that a combination of radiotherapy with immunoadjuvants 
improves abscopal response rates compared to using radio-
therapy alone.
However, the cure rates achieved with these combinations 
in clinical trials have not been as high, or the combinations 
as effective, as expected from preclinical studies. Hence, these 
studies have galvanized many ongoing studies investigating 
approaches that can more efficaciously use immunoadjuvants 
to prime the abscopal effect and increase cure rates for more 
patients (9, 25, 26). Besides, many current clinical trials 
(Table 2; Figure 2) are also focused on treating cancer patients 
with combined radiotherapy and immunotherapy. Although 
these studies do not necessarily investigate the abscopal effect, 
their results will contribute to useful insights for clinical absco-
pal treatment study.
rationaLe and Merits For UsinG 
sUBCUtaneoUs aUtoGraFts
Following the preclinical data
As highlighted in Table  1, a considerable amount of preclini-
cal work, which has successfully combined radiotherapy with 
immunoadjuvants, has involved the generation of subcutaneous 
tumors as the primary tumor in small animal models, and then 
priming the subcutaneous tumors to engender the abscopal 
effect. As an example, in the landmark study in 2004 (3), mice 
bearing subcutaneous syngeneic mammary carcinoma in 
both flanks were treated with the immunoadjuvant Fms-like 
tyrosine kinase receptor 3 ligand (Flt3-L) during radiotherapy. 
Flt3-L was employed to enhance the number of available APCs, 
which can take up the antigens after tumor irradiation. Flt3-L 
was administered after local radiation therapy to only 1 of the 
2 tumors. The second non-irradiated tumor was used as indi-
cator of the abscopal effect. Radiotherapy alone led to growth 
delay exclusively of the irradiated primary tumor. However, the 
non-irradiated tumor was also impaired by the combination of 
radiotherapy and Flt3-L.
FiGUre 1 | schematic of potential modus operandi for combining radiotherapy with immunoadjuvants to prime the abscopal effect more 
efficaciously.
taBLe 2 | a partial list of current clinical trials that study combined 
radiotherapy and immunotherapy (based on http://clinicaltrials.gov).
identifier study title
NCT03035890 Hypofractionated radiation therapy to improve immunotherapy 
response in non-small cell lung cancer
NCT02710643 “MIRO” molecularly oriented immuno-radiotherapy (FIL_MIRO)
NCT02579005 Radio-immuno-modulation in lung cancer
NCT02864615 Safety and preliminary efficacy of stereotactic body radiation 
therapy (SBRT) in patients with metastatic RCC treated with 
targeted or IO therapy
NCT02463994 A pilot study of MPDL3280A and HIGRT in metastatic none 
small cell lung cancer
NCT02839265 FLT3 ligand immunotherapy and stereotactic radiotherapy for 
advanced non-small cell lung cancer (FLT3)
NCT02710253 Phase II trial of salvage radiation therapy to induce 
systemic disease regression after progression on systemic 
immunotherapy
NCT03042156 Immunotherapy and palliative radiotherapy combined in patients 
with advanced malignancy
NCT02843165 Checkpoint blockade immunotherapy combined with 
stereotactic body radiation in advanced metastatic disease
NCT01436968 Phase 3 study of ProstAtak® immunotherapy with standard 
radiation therapy for localized prostate cancer (PrTK03)
NCT02677155 Sequential intranodal immunotherapy combined with anti-PD1 
(pembrolizumab) in follicular lymphoma (Lymvac-2)
NCT02239900 Ipilimumab and SBRT in advanced solid tumors
FiGUre 2 | number of ongoing clinical trials on combined 
radiotherapy and immunotherapy per disease site (summarized from 
the table 2).
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It is generally thought that the relative success of combining 
radiotherapy with immunoadjuvants in clinical trials represents 
an exquisite translation of such preclinical work. However, one 
could argue that the highly effective preclinical approach of 
generating and priming subcutaneous tumors has been only par-
tially translated to clinical trials. This is because the subcutaneous 
tumors in animals during preclinical studies have merely been 
viewed as expedient surrogates for the primary tumor, which will 
be irradiated in humans during clinical trials. This is understand-
able because patients already have primary tumors and there is 
little rationale to generate additional subcutaneous tumors on 
patients to serve as the primary tumor.
However, if one actually follows the preclinical data (Table 1), 
a relatively more accurate translation of these studies would be 
to also first generate a subcutaneous tumor on patients. This 
FiGUre 3 | illustration of (a) patient with local and metastatic tumor; (B) subcutaneous autograft generated; (C) treatment of subcutaneous tumor 
with radiotherapy and immunoadjuvant; (d) regression of autograft, primary tumor, and metastasis.
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subcutaneous tumor on the patient could then be treated as the 
primary tumor to prime an effective abscopal effect as in preclini-
cal studies (Figure 3). The patient’s original tumors would then 
instead serve as metastatic lesions. If effective, as suggested by the 
preclinical trial data, the immune-mediated abscopal effect would 
lead to regression of the subcutaneous tumor on the patient, 
along with any other tumors the patient has. So, following the 
preclinical data (Table 1), there is rationale for considering the 
use of subcutaneous tumor autografts in clinical trials employing 
immunoadjuvants with radiotherapy. However, more rigorous 
testing in preclinical studies may be needed to optimize such 
clinical trial planning.
Better Control of the priming process
Another reason for considering subcutaneous autografts in 
human trials is the potential for greater control of the priming 
process. The use of subcutaneous tumors provides an opportunity 
to begin irradiation when the tumor size and associated micro-
environment is optimal for priming the abscopal effect. Studies 
have suggested that the state of the tumor microenvironment and 
time of treatment is a factor in determining whether an effective 
abscopal effect is generated (4, 25). The use of subcutaneous 
models in human trials could afford more control, allowing to 
begin priming when optimal. Greater control also hearkens to 
better predictability toward treatment planning.
And with respect to treatment planning, use of subcutaneous 
autografts will also allow for choosing a convenient location to 
generate the tumor, farther away from more sensitive neighbor-
ing organs at risk (OAR). For example, instead of having to prime 
the abscopal effect using a lung tumor, which is near neighboring 
OAR like the heart, one could use a conveniently located subcuta-
neous tumor on the limbs (Figure 3). This may also be important 
for patients who need salvage radiotherapy but who have reached 
their neighboring OAR toxicity limitations, perhaps due to prior 
radiotherapy treatment. It would also allow for administering 
radiotherapy to a target where lymphopenia can be avoided (27). 
Furthermore, a convenient target would allow for hypofractiona-
tion, thus effectively reducing treatment times for patients (9, 28). 
Reducing the treatment times could also help with reducing costs. 
This is supported by recent studies (29) showing that the use of 
hypofractionation results in a significant reduction in the finan-
cial costs associated with treating breast cancer patients. Such a 
development will have major impact on the lives of millions of 
individuals living in low- and middle-income countries and other 
resource poor settings, who sometimes have to wait months to 
have access to radiotherapy treatment (28).
Using subcutaneous tumors may also provide more degrees of 
freedom for engineering the tumor microenvironment to make 
it more optimal for priming a robust or more efficacious abscopal 
effect. One could, for example, more conveniently use higher 
linear energy transfer (LET) radiation to make the tumors more 
immunogenic. Cancer immunogenicity is described as the ability 
of a tumor to induce an immune response. It is widely believed 
that tumor immunogenicity increases with the rate of mutations. 
The more mutations a tumor has during radiotherapy, the higher 
the chance that neoantigens can trigger an immune response. 
Bladder cancer, lung cancer, and melanoma are among the cancers 
with the highest rate of mutations and seem to have seen the high-
est abscopal response rates when combining radiotherapy and 
immunoadjuvants. Radiobiology indicates that certain types of 
radiotherapy beam qualities like high-LET radiation can generate 
more mutations in cancer cells. The use of subcutaneous tumors 
may provide opportunities to use more of such high-LET beams, 
which are less penetrating, to make tumors more immunogenic, 
hence potentially resulting in increased abscopal response rates.
In some preclinical studies showing abscopal effects, immu-
noadjuvants were administered via daily repeated injection in 
the subcutaneous tumors over many days after local radiation 
taBLe 3 | Merits and demerits of employing subcutaneous tumor 
autografts to prime a more efficacious abscopal effect.
Merits demerits
• Most preclinical studies demonstrating 
effective abscopal responses have employed 
subcutaneous models
• The skin layers are known to be highly populated 
with professional antigen-presenting cells, which 
play an important role in effectively inducing 
abscopal responses.
• There may be better control of the priming 
process when using subcutaneous tumors, since 
priming could be done at optimal tumor sizes or 
time points, etc.
• Radiotherapy treatment planning for priming the 
subcutaneous tumors should be easier if location 
is chosen distant from sensitive organs at risk.
• There is an opportunity to use smart biomaterial 
skin implants for sustained delivery of 
immunoadjuvants toward more effective treatment 
outcomes as seen in vaccine studies
• Benefits of this approach may outweigh the risks 
for certain groups of patients
• Subcutaneous 
tumors are expedient 
but provide limited 
recapitulation 
of the tumor 
microenvironment
• There is a need to 
first give patients 
an additional lesion 
before treating them
• Patients may 
reject autografts or 
homografts
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therapy (30). The use of subcutaneous tumors in human trials 
may make it easier to administer the immunoadjuvants, directly 
into the tumor even repeatedly with minimal systemic toxicities. 
This may particularly avail the use of immunoadjuvants like 
GM-CSF or anti-CD40, which enhance the recruitment and 
activation of APCs within the tumor. Furthermore, more potent 
immunoadjuvant combinations could be directly administered to 
the subcutaneous tumor to prime a robust immune response with 
minimal systemic toxicity. Combinations of immunoadjuvants 
have been shown to be more effective in immunotherapy but 
have been limited by systemic or overlapping toxicities reported 
in clinical trials (9).
The priming of antigen-specific effector T  cells is driven by 
proper antigen presentation and co-stimulation by APCs (31). 
Since APCs are localized, among other locations, in peripheral 
tissues such as the skin, the use of subcutaneous tumors may 
allow for targeting neoantigens to APCs where they are highly 
populated. Optimal subcutaneous APC targeting in combination 
with adequate adjuvant delivery may facilitate APC maturation 
and enhance antigen cross-presentation or T cell priming.
The use of subcutaneous tumors also provides an excellent 
opportunity to ensure adequate sustained immunoadjuvant deliv-
ery with minimal systemic toxicity by employing skin implant-
able biomaterials for sustained delivery of the immunoadjuvants. 
Examples of such biomaterials are smart radiotherapy biomaterials 
(32) (Figure  1) including microneedle versions loaded with 
immunoadjuvants for sustained in situ delivery as highlighted in 
recent studies (33). Studies have shown that sustained delivery 
of a vaccine using microneedles elicits increased proliferation of 
antigen-specific CD8+ T  cells compared to injections (34). The 
delivery of immunoadjuvant using skin implantable biomaterials 
with controlled release over many days is, therefore, expected 
to also prime a more robust and predictable immune response, 
consistent with previous work from vaccine studies. So altogether, 
compared to other approaches, slow in situ release of immunoad-
juvants would help minimize systemic toxicities and is expected to 
be more effective in priming an abscopal response (35).
deMerits For eMpLoyinG 
sUBCUtaneoUs aUtoGraFts
The approach to prime an abscopal effect using subcutaneous tumor 
autografts is tantamount to first giving a cancer patient more cancer 
in order to treat the patient. Such an approach is a challenge in at 
least two ways. First, there is a psychological challenge that must be 
overcome in explaining to patients why they will get more cancer 
first. However, if such an approach is shown to be more efficacious 
in human trials, the negative perception could be assuaged in the 
longer term. The location of the subcutaneous tumors could also 
be chosen where it can be effectively treated without significant 
additional burden to the patients. The strategic choice of location is 
one way used in surgery in research using tumor homografts (36).
Another thing to consider is that subcutaneous tumors do 
not fully recapitulate the tumor microenvironment. More studies 
designed to compare responses for orthotopic and subcutaneous 
tumors in priming effective abscopal responses may be needed to 
better address this concern.
In considering the use of subcutaneous tumors in human tri-
als, patient selection could also be the key. It may be advisable to 
start with patients with advanced or terminal metastatic disease. 
It is actually expected that these are the patients who could ini-
tially get the most benefit from this approach. So, clinical trials 
employing autografts would have to consider patient selection 
carefully. Apart from considering patients with advanced disease, 
the choice of tumor site may be a factor. Subcutaneous metastasis 
is rare but has been reported in some case studies (37–39). It 
may be worthy first testing in such patients who already have 
subcutaneous metastasis.
Another challenge is that patients may reject autografts. In a 
study by a number of authors, they concluded that patients with 
already advanced disease showed less rejection of subcutane-
ous tumors compared to normal people (40). For example, in 
a study by Southam and Moore, normal recipients responded 
to implanted cancer cells with a marked local inflammatory 
response and rapid complete regression of the implants in a 
maximum period of 3–4  weeks. However, in striking contrast, 
recipients who had advanced cancer showed little or no acute 
inflammatory response. Many patients failed to reject implanted 
cancer cells over periods of observation (40).
There is also a logistical question about how to get cells for 
the autograft. For many tumors, this could be obtained at time of 
biopsy or by fine needle aspiration of tumor tissue. In consider-
ing this logistical question, the possibility of using subcutaneous 
tumor homografts also arises. More investigations would be 
needed to see if one could employ homografts. Ultimately, 
the risks and benefits of subcutaneous tumors will need to be 
adequately balanced (Table 3).
FUrtHer disCUssion
Other than using subcutaneous tumor autograft, there are some 
differences between the preclinical and clinical studies that may 
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affect the treatment outcomes. For example, mice radiotherapy is 
typically done in a very different way than that of humans for the 
beam quality, field size, fractionation, radiation dose, etc. Some of 
these factors may not be adopted into the clinical studies. Others, 
when being adopted, may benefit from the flexibility provided by 
the subcutaneous tumor autograft.
There are ethics concerns involved in the new proposed treat-
ment scheme. Careful design of the clinical trials is necessary. The 
baseline of medicine and medical research is to act in the patient’s 
best interest (41). Medical research that involves human subjects 
should ensure safety, effectiveness, monitorable procedure, and 
predictable results; minimize the patient’s risks and burden; and 
provide the best possible care compared to all other alternatives 
(42). Based on these guidelines, clinical research for studying the 
subcutaneous tumor autograft may follow some recommenda-
tions as described in this section.
First of all, patients with terminal diseases may benefit from 
this treatment the most. To start with, the treatment may be tested 
in patients with subcutaneous metastasis (37–39, 43). In this case, 
there is no need for generating an autograft. Next, one would 
recommend continuing the study with stage IV none small cell 
lung cancer (NSCLC). Overall, lung cancer is the leading cause 
of cancer death for both men and women in the United States 
(44). For stage IV NSCLC patients, the 5-year survival rate is 
less than 10%, and the current treatment recommendation is to 
use chemotherapy. With the proposed treatment, if the abscopal 
effect is induced, the treatment outcome may exceed the current 
available options. Besides, previous studies (8) (Table  1) and 
current clinical trials (Table 2) with lung cancer patients provide 
valuable knowledge for research design.
Second, the patient’s risks and burden should be evaluated. 
With the current survival rate for stage IV NSCLC patients—less 
than 10% 5-year survival, which means the probability of death 
due to the cancer is close to 100%, it is almost impossible to 
increase patient’s risks. In fact, preclinical results are promising, 
and good chances of increasing the survival rate are expected. 
Furthermore, the proposed local treatment should minimize sys-
temic toxicity and reduce the patient’s burden. However, statistics 
for the entire patient population should never be confused with 
each individual case. For the actual clinical study, patients must 
be evaluated individually by their physicians and the clinical 
researchers.
Throughout the treatment, patients should be monitored 
closely for their response. The treatment site or the autograft 
can be easily measured for its response to radiotherapy. Imaging 
modalities, like CT and PET, can be used to assess the abscopal 
response. As reported by Golden et al., significantly lower neu-
trophil to lymphocyte ratio is presented in patients who have 
abscopal responses (8). Other methods, like T  cell trafficking 
(27), may also be useful for treatment monitoring.
ConCLUsion
Given the significant body of preclinical work showing the 
effectiveness of subcutaneous models in generating the abscopal 
effect, more preclinical studies designed to better assess the risks 
of generating subcutaneous autografts in clinical trials should 
first be considered to provide more data. Such studies could 
involve comparison with orthotopic tumor models. If the use 
of subcutaneous autografts is further justified by such data and 
validated, the impact of such an approach would be significant. 
It would further extend the use of radiotherapy to the treatment 
of both local and metastatic disease. Metastasis accounts for over 
90% of all cancer-associated suffering and death, hence, such an 
approach would be of great benefit to many cancer patients.
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